At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
OPA-15406 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Assess the Efficacy and Safety of 0.3% and 1% OPA-15406 Ointments in Patients With Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating OPA-15406 and Placebo for Atopic Dermatitis. Completed, enrolled 200 participants across 3 sites.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedSep 2016
Primary CompletionJun 2017
TodayJul 2026
First PostedSep 26, 2016
Enrollment StartSep 1, 2016
Primary CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.8 years ago
Interventions
OPA-15406drug
Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
Placebodrug
Subjects were treated with assigned 0% OPA-15406 ointment twice daily.